Market Overview

Teva Says Omacetaxine Mepesuccinate Shows Activity in CML

Share:
Related TEVA
Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
4 IBD 50 Drugmakers Getting Lift From New Treatments (Investor's Business Daily)

Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.

Posted-In: News FDA

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters